AI
ALLO icon

Atom Investors’s Allogene Therapeutics ALLO Stock Holding History

Atom Investors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-85,930
Closed -$107K – 570
2025
Q3 		$107K Buy
+85,930
New +$102K 0.01% 552
2024
Q3 		– Sell
-10,833
Closed -$25.2K – 467
2024
Q2 		$25.2K Buy
+10,833
New +$32K ﹤0.01% 454

Other funds holding ALLO

P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $646M AUM 291.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Atom Investors's ALLO Position: Q4 2025 in Review

Atom Investors sold out of Allogene Therapeutics (ALLO) in Q4 2025, closing a stake of 85,930 shares — an estimated $107K sold.

Atom Investors first reported a position in ALLO in Q2 2024 and held it in 2 quarters. The position peaked at $107K in Q3 2025. 172 funds tracked by Wall St. Rank hold ALLO as of Q4 2025.

  • Atom Investors reported no remaining Allogene Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Atom Investors sold 85,930 Allogene Therapeutics shares in Q4 2025, an estimated $107K.
  • Atom Investors first reported a position in Allogene Therapeutics in Q2 2024 and held it in 2 quarters.
  • Atom Investors's Allogene Therapeutics position peaked at $107K in Q3 2025.
  • 172 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2025.

Based on Atom Investors's 13F filing for Q4 2025, filed 17 Feb 2026.